Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

RBC Capital analyst Leonid Timashev maintained a Buy rating on Jazz Pharmaceuticals on April 6 and set a price target of $195.00. The company’s sha...

RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $232.00. According to TipRanks...

Piper Sandler Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Value stocks are shares of companies that appear undervalued relative to their fundamentals. This means their stock price looks low compared with w...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JAZZ	$195.66	+2.47%	687.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JAZZ	$195.66	+2.5%	687.05K
3
4
5
6

JAZZ

JAZZ

No Data Available

Get Jazz Pharmaceuticals plc Data in Excel

Get Jazz Pharmaceuticals plc Data in Excel